CRISPR-ERA for Switching Off (Onco) Genes

  • García-Tuñon I
  • Vuelta E
  • Pérez-Ramos S
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Genome-editing nucleases like the popular CRISPR/Cas9 enable the generation of knockout cell lines and null zygotes by inducing site-specific double-stranded breaks (DSBs) within a genome. In most cases, when a DNA template is not present, the DSB is repaired by nonhomologous end joining (NHEJ), resulting in small nucleotide insertions or deletions that can be used to construct knockout alleles. However, for several reasons, these mutations do not produce the desired null result in all cases, instead generating a similar protein with functional activity. This undesirable effect could limit the therapeutic efficiency of gene therapy strategies focused on abrogating oncogene expression by CRISPR/ Cas9 and should be taken into account. This chapter reviews the irruption of CRISPR technology for gene silencing and its application in gene therapy.

Cite

CITATION STYLE

APA

García-Tuñon, I., Vuelta, E., Pérez-Ramos, S., M Hernández-Rivas, J., Méndez, L., Herrero, M., & Sanchez-Martin, M. (2019). CRISPR-ERA for Switching Off (Onco) Genes. In Modulating Gene Expression - Abridging the RNAi and CRISPR-Cas9 Technologies. IntechOpen. https://doi.org/10.5772/intechopen.80245

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free